PMID: 30802022Mar 1, 2017Paper

Blood Transfusion Inspection

Rinsho byori. The Japanese journal of clinical pathology
Daisuke Ide

Abstract

Nearly one-half of all hematopoietic progenitor cell transplantation (HCT) procedures involve recipient- donor ABO incompatibility. ABO-incompatible HCT places the recipient at an increased risk of acute and delayed hemolytic reactions, delayed RBC engraftment, and pure red blood cell aplasia. Additionally, clinical and laboratory evaluations for potential non-ABO, minor RBC antigen-antibody discrepancies may be benefi- cial to facilitate safe transfusions before, during, and after transplantation. It is important for medical tech- nologists to play a role in ABO-incompatible HCT as members of the medical team. Medical technologists should obtain accurate laboratory data and analyze the outcomes in patients receiving ABO-incompatible HCT.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Garrett S BoothBipin N Savani
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie
Patricia M Kopko
© 2022 Meta ULC. All rights reserved